1. Home
  2. STXS vs UNCY Comparison

STXS vs UNCY Comparison

Compare STXS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$1.30

Market Cap

164.1M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$4.92

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STXS
UNCY
Founded
1990
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
145.3M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
UNCY
Price
$1.30
$4.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.00
$25.67
AVG Volume (30 Days)
1.2M
1.0M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$29,346,617.00
$675,000.00
Revenue This Year
$28.22
N/A
Revenue Next Year
$30.47
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.24
$3.72
52 Week High
$3.59
$8.74

Technical Indicators

Market Signals
Indicator
STXS
UNCY
Relative Strength Index (RSI) 32.44 40.57
Support Level N/A $4.28
Resistance Level $1.97 $5.39
Average True Range (ATR) 0.12 0.32
MACD -0.01 0.04
Stochastic Oscillator 10.16 20.26

Price Performance

Historical Comparison
STXS
UNCY

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: